Monoclonal gammopathy of clinical signifi cance with osteosclerotic lesions – a case report and a literature review

Česká verzia

Authors: Z. Adam ¹; Z. Řehák ²; M. Keřkovský ³; C. Povýšil ⁴; E. Ezer ⁵; A. Buliková ⁶; L. Pour ¹; M. Doubek ¹; Y. Stavařová ⁷; L. Zdražilová Dubská ⁸; P. Szutyany ⁹; S. Ševčíková ¹⁰; Z. Král ¹
Authors place of work: Interní hematologická a onkologická klinika LF MU a FN Brno ¹; Oddělení nukleární medicíny, MOU Brno ²; Klinika radiologie a nukleární medicíny LF MU a FN Brno ³; Ústav patologie, 1. LF UK a VFN v Praze ⁴; Oddělení patologie, Krajská nemocnice T. Bati, Zlín ⁵; Oddělení klinické hematologie, Interní hematologická a onkologická klinika LF MU a FN Brno ⁶; Oddělení klinické hematologie, Krajská nemocnice Tomáše Bati, Zlín ⁷; Katedra laboratorních metod, Ústav laboratorní medicíny, LF MU a FN Brno ⁸; Oddělení zobrazovacích metod, Krajská nemocnice T. Bati, Zlín ⁹; Ústav patologické fyziologie, LF MU Brno ¹⁰
Published in the journal: Klin Onkol 2024; 38(3): 209-219
Category: Kazuistiky
doi: https://doi.org/10.48095/ccko2024209

Summary

Introduction: Multiple myeloma is a common plasma cell neoplasia usually accompanied by the formation of osteolytic foci, whereas osteosclerotic myeloma is a very rare form of plasma cell dyscrasia. When osteosclerotic myeloma is detected, osteosclerotic foci are usually part of the POEMS syndrome. Osteosclerotic myeloma without other manifestations of the POEMS syndrome is an unusual finding. Case description: In a 46-year-old woman, osteosclerotic changes of the temporoparietal region caused soft tissue induration over this lesion, which initiated further investigation. Imaging studies subsequently showed multiple osteosclerotic foci in the skull. Examination of blood proteins revealed 8 g/L of IgG-lambda monoclonal immunoglobulin, subclass IgG1. In search of the cause of the osteosclerotic changes, FDG-PET/CT was performed, which revealed no FDG accumulation, i.e., no other tumor (breast or stomach cancer). Low-dose CT showed irregular bone structure, but not significant osteolytic or osteosclerotic foci. To map the extent of osteosclerotic changes, NaF-PET/CT imagination followed, which revealed multiple spots with high fluoride accumulation. A parietal bone biopsy showed osteosclerosis with minor clonal plasma cell infiltration. Trepanobioptic bone marrow sampling revealed an infiltration of bone marrow with atypical plasma cells in 8%. Flow-cytometric examination of bone marrow showed 0,37% of plasma cells, however predominantly (91%) clonal with lambda expression. MRI of the brain identified asymptomatic meningeal thickening. There was no evidence of POEMS syndrome in the patient; thus, we concluded the diagnosis as monoclonal gammopathy of clinical significance with osteosclerosis which was previously termed osteosclerotic multiple myeloma. Conclusion: Monoclonal gammopathy of clinical significance (MGCS) with osteosclerotic skeletal changes, documented on CT and multiple foci with intensive osteoneogenesis, documented on NaF-PET/CT without evidence of POEMS syndrome, is an extremely rare form of plasma cell dyscrasia. This publication documents the unique clinical manifestations of IgG-lambda type plasma cell proliferation without signs of POEMS syndrome and the role of NaF-PET/CT imaging. Classification of this disease as MGSC with osteosclerotic manifestations is more consistent with the indolent nature of the disease with a significantly better prognosis, compared with multiple myeloma.

Keywords:

POEMS syndrome – osteosclerotic myeloma – monoclonal gammopathy of clinical significance (MGCS) with osteosclerosis – osteosclerosis

Zdroje

1. Krejčí D, Svobodová I, Zapletalová M et al. Epidemiology of multiple myeloma in the Czech Republic Klin Onkol 2017; 30 (Suppl 2): 35–42. doi: 10.14735/amko20172 S35.

2. Česká myelomová skupina. Souhrn doporučení 2023: diagnostika a léčba mnohočetného myelomu. Trans Hematol Dnes 2023; 29 (Suppl 2): 10–23.

3. Minařík J, Zemanová M, Bačovský J et al. POEMS syndrom. Vnitr Lek 2008; 54 (5): 566–567.

4. Minařík J. Diagnostika a léčba POEMS syndromu. In: Hematologie a hematoonkologie v kazuistikách. Praha: Maxdorf 2020: 174–177.

5. Minařík J, Ščudla V, Bačovský V et al. Monitorování VEGF v průběhu POEMS syndromu. Trans Hematol Dnes 2010; 16 (Suppl 2): 114.

6. Minařík J, Ščudla V, Bačovský J et al. POEMS syndrom. Onkologie 2011; 5 (3): 151–154.

7. Fermand JP, Bridoux F, Dispenzieri A et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood 2018; 132 (14): 1478–1485. doi: 10.1182/blood-2018-04-839480.

8. Go RS, Rajkumar SV. How I manage monoclonal gammopathy of undetermined significance. Blood 2018; 131 (2): 163–173. doi: 10.1182/blood-2017-09-807 560.

9. Dispenzieri A. Monoclonal gammopathies of clinical significance. Hematology Am Soc Hematol Educ Program 2020; 2020 (1): 380–388. doi: 10.1182/hematology.2020000122.

10. Adam Z, Pour L, Zeman D et al. Monoklonální gamapatie klinického významu a jiné nemoci. Grada Publishing: Praha 2023.

11. Sharnoff JG, Belsky H, Melton J. Plasma cell leukemia or multiple myeloma with osteosclerosis. Am J Med 1954; 17 (4): 582–584. doi: 10.1016/0002-9343 (54) 90134-5.

12. Wiedermann B, Krč C, Soyka O et al. Plasmocytoma with generalized osteosclerosis. Folia Haematol Int Mag Klin Morphol Blutforsch 1966; 86 (1): 47–69.

13. Divakar M, Shyam A, Hadgaonkar S et al. Osteosclerotic multiple myeloma without POEMS syndrome – a rare case report. J Orthop Case Rep 2022; 12 (1): 18–21. doi: 10.13107/jocr.2022.v12.i01.2598.

14. Terao T, Matsue K. Osteosclerotic myeloma without features of POEMS syndrome. Int J Hematol 2019; 110 (5): 517–518. doi: 10.1007/s12185-019-02718-7.

15. Zheng W, Low MSY. Rare presentation of myeloma with diffuse osteosclerotic lesions without features of POEMS. Ann Hematol 2022; 101 (2): 429–430. doi: 10.1007/s00277-021-04455-6.

16. Lacy MQ, Gertz MA, Hanson CA et al. Multiple myeloma associated with diffuse osteosclerotic bone lesions: a clinical entity distinct from osteosclerotic myeloma (POEMS syndrome). Am J Hematol 1997; 56 (4): 288–293. doi: 10.1002/ (sici) 1096-8652 (199712) 56: 4<288:: aid-ajh16>3.0.co; 2-5.

17. Reitan JB, Pape E, Fosså SD et al. Osteosclerotic myeloma with polyneuropathy. Acta Med Scand 2009; 208 (1–2): 137–144. doi: 10.1111/j.0954-6820.1980.tb01167.x.

18. Sartoris DJ, Pate D, Haghighi P et al. Plasma cell sclerosis of bone: a spectrum of disease. Can Assoc Radiol J 1986; 37 (1): 25–34.

19. Hall FM, Gore SM. Osteosclerotic myeloma variants. Skeletal Radiol 1988; 17 (2): 101–105. doi: 10.1007/BF00 365135.

20. Waldenström JG, Adner A, Gydell K et al. Osteosclerotic „plasmocytoma“ with polyneuropathy, hypertrichosis and diabetes. Acta Med Scand 1978; 203 (4): 297–303. doi: 10.1111/j.0954-6820.1978.tb14877.x.

21. Bardwick PA, Zvaifler NJ, Gill GN et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine 1980; 59 (4): 311–322. doi: 10.1097/00005792-198007000-00006.

22. Suichi T, Misawa S, Beppu M et al Prevalence, clinical profiles, and prognosis of POEMS syndrome in Japanese nationwide survey. Neurology 2019; 93 (10): e975–e983. doi: 10.1212/WNL.0000000000008062.

23. Dispenzieri A. POEMS syndrome: update on diagnosis, risk-stratification, and management. Am J Hematol 2023; 98 (12): 1934–1950. doi: 10.1002/ajh.27081.

24. Kuo MC, Shih LY. Primary plasma cell leukemia with extensive dense osteosclerosis: complete remission following combination chemotherapy. Ann Hematol 1995; 71 (3): 147–151. doi: 10.1007/BF01702651.

25. Chen M, Green R. Circulating plasma cells with Russell bodies in osteosclerotic myeloma. Blood 2013; 122 (2): 160. doi: 10.1182/blood-2013-01-479154.

26. Mulleman D, Gaxatte C, Guillerm G et al. Multiple myeloma presenting with widespread osteosclerotic lesions. Joint Bone Spine 2004; 71 (1): 79–83. doi: 10.1016/S1297-319X (03) 00152-0.

27. Crispin PJ, Cheah PL. Autoimmune haemolytic anaemia and neuropathy with IgA osteosclerotic myeloma: a case report. Pathology 2017; 49 (6): 646–647. doi: 10.1016/j.pathol.2017.04.009.

28. Vignon M, Senot N, Bousson V et al. A case of multiple myeloma presenting with diffuse osteosclerosis and multiple bone infarcts. Joint Bone Spine 2018; 85 (5): 631–633. doi: 10.1016/j.jbspin.2017.11.013.

29. Grover SB, Dhar A. Imaging spectrum in sclerotic myelomas: an experience of three cases. Eur Radiol 2000; 10 (11): 1828–1831. doi: 10.1007/s003300000499.

30. McCluggage WG, Jones FG, Hull D et al Sclerosing IgA multiple myeloma. Acta Haematol 1995; 94 (2): 98–101. doi: 10.1159/000203982.

31. Somaratne SC, Darmasena CS, Arachchi WK et al. A middle-aged man with monoclonal gammopathy and osteopetrosis. Ceylon Med J 2007; 52 (2): 62–63. doi: 10.4038/cmj.v52i2.1026.

32. Mazzeo A, Granata F, Vinci S et al. Osteosclerotic myeloma with spinal leptomeningitis and severe polyneuropathy: a case report. J Comput Assist Tomogr 2006; 30 (4): 649–652. doi: 10.1097/00004728-200607000-00 016.

33. Hara D, Akiyama H, Nukui S et al. Utility of osteosclerotic lesion biopsy in diagnosis of POEMS syndrome: a case report. Medicine 2017; 96 (41): e8188. doi: 10.1097/MD.0000000000008188.

34. Quattrocchi CC, Piciucchi S, Sammarra M et al. Bone metastases in breast cancer: higher prevalence of osteosclerotic lesions. Radiol Med 2007; 112 (7): 1049–1059. doi: 10.1007/s11547-007-0205-x.

35. Anagnostopoulos G, Sakorafas GH, Kostopoulos P et al. Early (mucosal) gastric cancer with synchronous osteosclerotic bone metastases: a case report. Eur J Cancer Care 2010; 19 (4): 554–557. doi: 10.1111/j.1365-2354.2007.00847.x.

36. Varyani N, Thukral A, Garg S et al. Atypical neurofibroma and osteosclerotic metastasis. Case Rep Oncol Med 2012; 2012: 301437. doi: 10.1155/2012/301437.

37. Král Z, Adam Z. Histiocytární neoplazie a další vybrané velmi vzácné krevní nemoci. Praha: Grada Publishing 2020.

38. Yuxin Li, Schiepers Ch, Lake R et al. Clinical utility of 18F-fluoride PET/CT in benign and malignant bone diseases. Bone 2012; 50 (1): 128–139. doi: 10.1016/ j.bone.2011.09.053.

39. Marafi FAR, Rasheed R, Usmani S et al. Significance of F18-sodium fluoride positron emission tomography in characterization of POEMS osteosclerotic lesions better then F18-fluorodeoxyglucose positron emission tomography. Indian J Nucl Med 2018; 33 (1): 76–78. doi: 10.4103/ijnm.IJNM_125_17.

40. Minařík J, Ščudla V, Bačovský J et al. Comparison of imaging methods in POEMS syndrome. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2012; 156 (1): 52–57. doi: 10.5507/bp.2011.053.

41. Fan Z, Wang T, Zou L et al. Comparison of the diagnostic value of 18F-NaF PET/CT and <sup>99m</sup>Tc-MDP SPECT for bone metastases: a systematic review and meta-analysis. Transl Cancer Res 2023; 12 (11): 3166–3178. doi: 10.21037/tcr-23-817.

42. Ueda F, Okuda M, Aburano H et al. Cranial pachymeningeal involvement in POEMS syndrome: evaluation by pre- and post-contrast FLAIR and T<sub>1</sub>-weighted imaging. Magn Reson Med Sci 2017; 16 (3): 231–237. doi: 10.2463/mrms.mp.2015-0014.

43. Briani C, Manara R, Lessi F et al. Pachymeningeal involvement in POEMS syndrome: dramatic cerebral MRI improvement after lenalidomide therapy. Am J Hematol 2012; 87 (5): 539–541. doi: 10.1002/ajh.23148.

44. Briani C, Fedrigo M, Manara R et al.Pachymeningeal involvement in POEMS syndrome: MRI and histopathological study. J Neurol Neurosurg Psychiatry 2012; 83 (1): 33–37. doi: 10.1136/jnnp-2011-300047.

45. Ziff OJ, Hoskote C, Keddie S et al. Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome. J Neurol 2019; 266 (5): 1067–1072. doi: 10.1007/s00415-019-09233-z.

46. Mohamed M, Brain T, Khalafallah A. Dramatic response of diffuse osteosclerosis secondary to multiple myeloma using thalidomide with melphalan and prednisolone. J Clin Oncol 2014; 32 (23): e85–e87. doi: 10.1200/JCO.2012.48.0111.

47. Vaxman I, Kumar SK, Buadi F et al. Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: the Mayo clinic experience. Blood Cancer J 2023; 13 (1): 91. doi: 10.1038/s41408-023-00859-x.

48. Gavriatopoulou M, Ntanasis-Stathopoulos I, Fotiou D et al. Upfront daratumumab with lenalidomide and dexamethasone for POEMS syndrome. Hemasphere 2020; 4 (3): e381. doi: 10.1097/HS9.0000000000000381.

49. Khwaja J, Keh R, Smyth D et al. Daratumumab-bortezomib-dexamethasone use in relapsed POEMS syndrome. EJHaem 2022; 3 (3): 1021–1024. doi: 10.1002/jha2.492.

50. Tiew HW, Sampath VS, Gallardo CA et al. Single-agent daratumumab for refractory POEMS syndrome. Am J Hematol 2022; 97 (6): E189–E191. doi: 10.1002/ajh.26517.

51. Dima D, Valent J, Khouri J. Daratumumab monotherapy for relapsed POEMS syndrome. Am J Hematol 2023; 98 (11): E291–E294. doi: 10.1002/ajh.27050.

52. Oyama T, Taoka K, Chiba A et al. Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion. Int J Hematol 2023; 117 (3): 463–467. doi: 10.1007/s12185-022-03459-w.

53. Sternberg AJ, Davies P, Macmillan C et al. Strontium-89: a novel treatment for a case of osteosclerotic myeloma associated with life-threatening neuropathy. Br J Haematol 2002; 118 (3): 821–824. doi: 10.1046/j.1365-2141.2002.03692.x.

54. Pika T, Minařík J, Piková K et al. Osteosklerotická forma mnohočetného myelomu a POEMS syndrom – diagnostické aspekty. Osteol Bull 2015; 20 (2): 84.

55. Král Z, Krejčí M, Pour L et al. POEMS syndrom – vzácné onemocnění asociované s monoklonální gamapatií a polyneuropatií: diagnostika a terapie. Trans Hematol Dnes 2021; 27 (3): 226–231. doi: 10.48095/cctahd2021226.